Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Stoten will be taking over from retiring Managing Director Linda Naylor from April.

Oxford University Innovation (OUI), the research commercialisation company of Oxford University, has named its new Chief Operating Officer (COO). Dr Adam Stoten, the current Head of Technology Transfer Life Sciences at OUI, will be taking up the newly-created position from 1st April 2017.

Stoten, who holds a PhD in Immunology from the University of Nottingham, has been a leading figure at OUI since 2005 when he joined the company as a Project Manager. In 2010, he joined the Oxford-Emergent Tuberculosis Consortium, a joint venture between Oxford University and Emergent BioSolutions, which conducted the first ever efficacy study of a new tuberculosis vaccine in infants. He remained with the spinout until 2013 as its Deputy General Manager, before returning to OUI to head up its life sciences commercialisation activities.

Read more (Oxford University Innovation website)